US Patent

US10849891 — Formulations of pimavanserin

Method of Use · Assigned to Acadia Pharmaceuticals Inc · Expires 2038-08-27 · 12y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations of pimavanserin, including capsules containing the drug and processes for manufacturing them.

USPTO Abstract

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

Drugs covered by this patent

pimavanserin-tartrate (PIMAVANSERIN TARTRATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1974`	—	pimavanserin-tartrate

Patent Metadata

Patent number: US10849891
Jurisdiction: US
Classification: Method of Use
Expires: 2038-08-27
Drug substance claim: No
Drug product claim: Yes
Assignee: Acadia Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.